Abstract Treatment options for triple-negative breast cancer (TNBC) remain extremely limited, and patients have a poor prognosis. Although chimeric antigen receptor (CAR)-T cell therapy has achieved breakthroughs in haematological malignancies, its application in solid tumours such as TNBC is hampered by challenges including antigenic heterogeneity, immune evasion, and off-target toxicity.
Integrated Chinese
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Integrated
Contact Integrated, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack